KR20240150426A - 비경구 호흡 자극제 제형 - Google Patents

비경구 호흡 자극제 제형 Download PDF

Info

Publication number
KR20240150426A
KR20240150426A KR1020247025381A KR20247025381A KR20240150426A KR 20240150426 A KR20240150426 A KR 20240150426A KR 1020247025381 A KR1020247025381 A KR 1020247025381A KR 20247025381 A KR20247025381 A KR 20247025381A KR 20240150426 A KR20240150426 A KR 20240150426A
Authority
KR
South Korea
Prior art keywords
formulation
compound
substituted
parenteral formulation
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247025381A
Other languages
English (en)
Korean (ko)
Inventor
조셉 브이. 페르골리지
프랭크 다이애나
지아이 첸
데본 이. 도드
아이작 아계망
Original Assignee
에날레어 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에날레어 테라퓨틱스 인크. filed Critical 에날레어 테라퓨틱스 인크.
Publication of KR20240150426A publication Critical patent/KR20240150426A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020247025381A 2021-12-27 2022-12-23 비경구 호흡 자극제 제형 Pending KR20240150426A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163293985P 2021-12-27 2021-12-27
US63/293,985 2021-12-27
US202263313472P 2022-02-24 2022-02-24
US63/313,472 2022-02-24
PCT/US2022/053935 WO2023129502A1 (en) 2021-12-27 2022-12-23 Respiratory stimulant parenteral formulations

Publications (1)

Publication Number Publication Date
KR20240150426A true KR20240150426A (ko) 2024-10-15

Family

ID=86992921

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247025381A Pending KR20240150426A (ko) 2021-12-27 2022-12-23 비경구 호흡 자극제 제형

Country Status (9)

Country Link
US (1) US20230210857A1 (enExample)
EP (1) EP4456900A4 (enExample)
JP (1) JP2025501169A (enExample)
KR (1) KR20240150426A (enExample)
AU (1) AU2022426492A1 (enExample)
CA (1) CA3242509A1 (enExample)
MX (1) MX2024008162A (enExample)
TW (1) TW202333732A (enExample)
WO (1) WO2023129502A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4543455A4 (en) * 2022-06-24 2026-06-03 Enalare Therapeutics Inc METHODS OF TREATMENT FOR NEUROLOGICAL VENTILATORY FAILURE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
SG10201601507YA (en) * 2010-11-29 2016-04-28 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2012250050B2 (en) * 2011-04-28 2017-04-06 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
BR112015011213A2 (pt) * 2012-11-15 2017-08-29 Galleon Pharmaceuticals Inc Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.
GB201502412D0 (en) * 2015-02-13 2015-04-01 Canbex Therapeutics Ltd Therapeutic use

Also Published As

Publication number Publication date
EP4456900A1 (en) 2024-11-06
TW202333732A (zh) 2023-09-01
WO2023129502A1 (en) 2023-07-06
US20230210857A1 (en) 2023-07-06
MX2024008162A (es) 2024-09-17
JP2025501169A (ja) 2025-01-17
EP4456900A4 (en) 2025-12-24
CA3242509A1 (en) 2023-07-06
AU2022426492A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
US20230310440A1 (en) Respiratory stimulant nasal formulations
EP1371355B1 (en) UV-protection formulations
US20250032496A1 (en) Methods of treating respiratory depression modulated by a non-opioid agent
US20250114370A1 (en) Methods and compositions for treating drug overdose
JP2024517463A (ja) ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法
RU2011146005A (ru) Композиции для лечения воспаления и способы лечения воспаления
KR20160093089A (ko) 미용 조성물의 안정화
US20230210857A1 (en) Respiratory stimulant parenteral formulations
CA3217969A1 (en) Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof
US20230414624A1 (en) Methods of treating neurological ventilatory insufficiency
US20240238303A1 (en) Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof
CN118829433A (zh) 呼吸刺激剂肠胃外制剂
TW202529771A (zh) 用於治療藥物過量的方法及組合物
HK40100733A (en) Scar treatment composition
DK160034B (da) Farmaceutisk praeparat, isaer til behandling af cardiovasculaere lidelser

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000